FGF2, an Immunomodulatory Factor in Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Yuanyang Tan; Yongkang Qiao; Zhuanggui Chen; Jing Liu; Yanrong Guo; Thai Tran; Kai Sen Tan; De-Yun Wang; Yan Yan

doi:10.3389/fcell.2020.00223

FGF2, an Immunomodulatory Factor in Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Front Cell Dev Biol. 2020 Apr 2:8:223. doi: 10.3389/fcell.2020.00223. eCollection 2020.

Authors

Yuanyang Tan¹, Yongkang Qiao², Zhuanggui Chen³, Jing Liu⁴, Yanrong Guo¹, Thai Tran⁵, Kai Sen Tan⁶, De-Yun Wang⁶, Yan Yan^{1

7}

Affiliations

¹ Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
² BGI-Shenzhen, Shenzhen, China.
³ Department of Pediatrics, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
⁴ Department of Respiratory Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
⁵ Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
⁶ Department of Otolaryngology, Yong Loo Lin School of Medicine, University Health System, National University of Singapore, Singapore, Singapore.
⁷ Center for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.

Abstract

The fibroblast growth factor 2 (FGF2) is a potent mitogenic factor belonging to the FGF family. It plays a role in airway remodeling associated with chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). Recently, research interest has been raised in the immunomodulatory function of FGF2 in asthma and COPD, through its involvement in not only the regulation of inflammatory cells but also its participation as a mediator between immune cells and airway structural cells. Herein, this review provides the current knowledge on the biology of FGF2, its expression pattern in asthma and COPD patients, and its role as an immunomodulatory factor. The potential that FGF2 is involved in regulating inflammation indicates that FGF2 could be a therapeutic target for chronic inflammatory diseases.

Keywords: airway structural cells; asthma; chronic obstructive pulmonary disease; fibroblast growth factor 2; immunomodulation therapeutics.

Publication types

Review